IRIS
MORSIA, Erika
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.096
AS - Asia 1.312
EU - Europa 1.003
SA - Sud America 368
Continente sconosciuto - Info sul continente non disponibili 155
AF - Africa 104
OC - Oceania 2
Totale 5.040
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.018
IT - Italia 362
SG - Singapore 354
VN - Vietnam 334
BR - Brasile 275
CN - Cina 248
RU - Federazione Russa 213
HK - Hong Kong 134
FR - Francia 87
DE - Germania 71
BD - Bangladesh 65
IE - Irlanda 51
IN - India 48
CI - Costa d'Avorio 46
GB - Regno Unito 43
AR - Argentina 38
FI - Finlandia 38
NL - Olanda 38
MX - Messico 34
CA - Canada 28
SE - Svezia 21
AT - Austria 20
ID - Indonesia 17
MA - Marocco 17
JP - Giappone 16
PL - Polonia 16
ES - Italia 14
EC - Ecuador 13
VE - Venezuela 13
IQ - Iraq 12
ZA - Sudafrica 12
TR - Turchia 11
CO - Colombia 9
PE - Perù 8
TH - Thailandia 8
UZ - Uzbekistan 8
AE - Emirati Arabi Uniti 6
CR - Costa Rica 6
PH - Filippine 6
PK - Pakistan 6
PY - Paraguay 6
CL - Cile 5
KR - Corea 5
SN - Senegal 5
TN - Tunisia 5
AZ - Azerbaigian 4
CZ - Repubblica Ceca 4
EG - Egitto 4
JO - Giordania 4
KZ - Kazakistan 4
LT - Lituania 4
MY - Malesia 4
NP - Nepal 4
DO - Repubblica Dominicana 3
DZ - Algeria 3
SA - Arabia Saudita 3
AL - Albania 2
BW - Botswana 2
ET - Etiopia 2
GR - Grecia 2
HU - Ungheria 2
JM - Giamaica 2
KE - Kenya 2
MT - Malta 2
PT - Portogallo 2
RS - Serbia 2
TW - Taiwan 2
TZ - Tanzania 2
UA - Ucraina 2
AU - Australia 1
BB - Barbados 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
CH - Svizzera 1
GA - Gabon 1
GE - Georgia 1
GI - Gibilterra 1
GT - Guatemala 1
HN - Honduras 1
HR - Croazia 1
IL - Israele 1
IR - Iran 1
KG - Kirghizistan 1
LB - Libano 1
LU - Lussemburgo 1
MD - Moldavia 1
MN - Mongolia 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PA - Panama 1
PS - Palestinian Territory 1
SY - Repubblica araba siriana 1
TG - Togo 1
UY - Uruguay 1
VC - Saint Vincent e Grenadine 1
XK - ???statistics.table.value.countryCode.XK??? 1
ZW - Zimbabwe 1
Totale 4.886
Salva come PNG Salva come JPEG
Città #
Ashburn 485
Singapore 216
Dallas 198
San Jose 168
Council Bluffs 148
Hong Kong 128
Ho Chi Minh City 116
Los Angeles 97
Boardman 91
Hanoi 79
Beijing 57
Dublin 51
Hefei 50
New York 49
Abidjan 46
Lauterbourg 45
Ancona 42
Munich 40
Chandler 38
Chicago 36
Buffalo 35
Milan 35
Moscow 34
The Dalles 29
Helsinki 25
Santa Clara 25
São Paulo 24
Denver 23
Orem 22
Rome 22
Turin 19
Brooklyn 18
Washington 17
Salt Lake City 16
Chennai 15
Frankfurt am Main 15
Haiphong 15
Mexico City 15
Amsterdam 13
Turku 13
Da Nang 11
London 11
Tokyo 11
Warsaw 11
Guangzhou 10
San Francisco 10
Seattle 10
Bari 9
Houston 9
Nuremberg 9
Stockholm 9
Boston 8
Montreal 8
Shanghai 8
Tashkent 8
Manchester 7
Mumbai 7
Naples 7
Phoenix 7
Rio de Janeiro 7
Atlanta 6
Caracas 6
Elk Grove Village 6
Hải Dương 6
Johannesburg 6
Miami 6
Ninh Bình 6
Tampa 6
Vienna 6
Baghdad 5
Bangkok 5
Can Tho 5
Columbus 5
Dakar 5
Falconara Marittima 5
Lima 5
Medellín 5
New Delhi 5
North Charleston 5
Osimo 5
Palermo 5
Paris 5
San José 5
Toronto 5
Wuhan 5
Andria 4
Baku 4
Biên Hòa 4
Bologna 4
Brasília 4
Campinas 4
Cardiff 4
Charlotte 4
City of London 4
Clifton 4
Fortaleza 4
Guarulhos 4
Guayaquil 4
Huế 4
Lawrence 4
Totale 2.981
Salva come PNG Salva come JPEG
Nome #
Epidemiology of cutaneous T-cell lymphomas: state of the art and a focus on the Italian Marche region 166
Uncommon Presentation of Sarcoidosis with Severe Thrombocytopenia and Hemorrhagic Diathesis 161
Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report 157
Shaping the Future of Myeloproliferative Neoplasm Therapy: Immune-Based Strategies and Targeted Innovations 155
Clinicopathological, cytogenetic, and molecular profiles of primary cutaneous diffuse large B-cell lymphomas 140
A rare case of aCML associated with CNS involvement and with aggressive clinical course 138
Molecular Pathogenesis of Myeloproliferative Neoplasms: From Molecular Landscape to Therapeutic Implications 132
NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES 129
Bone Marrow Adipose Tissue 124
Anticoagulation and vessel recanalization in cirrhotic patients with splanchnic vein thrombosis: A multidisciplinary “real life” experience 123
Prognosis in early stage cutaneous T-cell lymphoma treated with psoralen plus ultraviolet A irradiation and low-dose interferon-α: Long-term efficacy and survival according to conventional and emerging clinical endpoints 119
Prevalence of Type 1 Gaucher Disease in Patients with Multiple Myeloma: Updated Interim Analysis of a Prospective, Multicentre, Observational Study 117
D-dimer and reduced-dose apixaban for extended treatment after unprovoked venous thromboembolism: the Apidulcis study 112
Chronic Myelomonocytic Leukemia Diagnosis By Flow Cytometry: An Italian Center Experience 112
Frequency and Risk Factors for Venous Thromboembolism Among Patients with Multiple Myeloma or Aggressive Lymphoma: A 6-Year Single Center Retrospective Analysis 111
Hepatic, gastric and bone marrow AL amyloidosis that began with Budd-Chiari syndrome: a case report 109
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients 107
Clinical Presentation, Risk Factors and Outcome of Splanchnic Venous Thrombosis: A Report on 305 Cases 107
AL amyloidosis: an overview on diagnosis, staging system, and treatment 107
Novel Immunotherapies and Combinations: The Future Landscape of Multiple Myeloma Treatment 106
Clinico-Pathological, Cytogenetic and Molecular Similarities and Differences between Primary and Secondary Cutaneous Lymphomas 105
Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights 102
Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort 101
Pediatric primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: A retrospective analysis and review of the literature 99
Cutaneous T-cell lymphoma care across Europe: insights from the Horizon Project 99
Transfusion dependence is a risk factor for severe infections in myelodysplastic syndromes 98
Is There a Correlation Between Immune Thrombocytopenia and Immunoglobulin G4-Related Disease? 98
Prevalence of type I Gaucher disease in patients with smoldering or multiple myeloma: Results from the prospective, observational CHAGAL study 97
Myeloproliferative Neoplasms with Monocytosis 92
The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management 85
P1045: IS JAK2V617F BUT NOT CALR AS DRIVER MUTATION ENOUGH BY ITSELF IN THE PATHOGENESIS OF UNUSUAL TYPE VENOUS THROMBOSIS IN MPN PATIENTS? 84
Expression of Paraoxonase-2 in Different Stages of Cutaneous T Cell Lymphoma: Is It a Potential Biomarker for Aggressiveness? 84
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI) 83
Epidemiology and Risk Factors for Infections in Myelodysplastic Syndromes 81
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy 79
Clinical outcomes of ruxolitinib treatment in 595 intermediate-1 risk patients with myelofibrosis: The RUX-MF Real-World Study 75
Multidisciplinary and personalized approach to the management of mycosis fungoides with chlormethine gel: a collection of clinical experiences 74
Myelofibrosis: challenges for preclinical models and emerging therapeutic targets 73
Cytogenetic Features and Their Implications in Clinical Practice: A Real-World Analysis of a Large Cohort of Multiple Myeloma Patients 70
Sequential Bispecific Antibodies in Functional and Clinical High Risk Multiple Myeloma, Manifesting with Extramedullary Disease at Relapse: A Case Report 69
Long-Term Efficacy of Psoralen Plus Ultraviolet a Irradiation and Low-Dose Interferon-Alpha Therapy According to Conventional and Emerging Clinical Endopoints of Early Stage Cutaneous T Cell Lymphoma 68
WHO defined chronic eosinophilic leukemia, not otherwise specified (CEL, NOS): A contemporary series from the Mayo Clinic 67
Disease Phenotype Significantly Influences the Outcome After Discontinuation of Ruxolitinib in Chronic Phase Myelofibrosis 66
Impact of ELN clinical signs and symptoms on the thrombotic risk in polycythemia vera patients treated with front-line hydroxyurea 64
Mutations and thrombosis in essential thrombocythemia 63
Venetoclax plus hypomethylating agent in blast-phase myeloproliferative neoplasm: preliminary experience with 12 patients 61
Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome 61
IDH2 Inhibitor Therapy in Relapsed and Refractory Acute Myeloid Leukemia: A Single Institution Experience 59
Paraoxonase-2 in cutaneous T cell lymphomas. 58
Erythroid-stimulating agents in VEXAS syndrome: A retrospective study from an Italian multicentre cohort 56
Ruxolitinib after fedratinib failure in patients with myelofibrosis: A real-world case series 51
Treatment strategies and survival after ruxolitinib discontinuation in myelofibrosis patients: The Italian RUX-MF multicenter study 51
The Strange Case of Functional High-Risk Multiple Myeloma Patients: Is It Possible to Identify Them in Clinical Practice? 19
Genetic insights into myeloproliferative neoplasms and unusual sites thrombosis 16
Totale 5.040
Salva come PNG Salva come JPEG
Categoria #
all - tutte 21.574
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.574
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202223 0 1 0 0 0 1 3 2 0 3 6 7
2022/2023157 6 9 7 12 7 9 1 9 26 0 60 11
2023/2024378 37 12 38 44 57 54 11 13 3 28 15 66
2024/20251.011 66 66 38 19 31 53 96 24 171 55 193 199
2025/20263.250 213 252 295 384 311 253 525 260 246 260 128 123
2026/2027214 156 58 0 0 0 0 0 0 0 0 0 0
Totale 5.040